Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

This phase I study aimed at determining the maximum tolerated dose (MTD) and characterizing the safety, tolerability, pharmacokinetics (PKs), and efficacy of pasireotide in patients with advanced neuroendocrine tumors (NETs). Patients were enrolled in two phases: dose-escalation phase (to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, James C, Chan, Jennifer A, Mita, Alain C, Kundu, Madan G, Hermosillo Reséndiz, Karina, Hu, Ke, Ravichandran, Shoba, Strosberg, Jonathan R, Wolin, Edward M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499931/
https://www.ncbi.nlm.nih.gov/pubmed/28721067
http://dx.doi.org/10.2147/OTT.S128547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499931/
https://www.ncbi.nlm.nih.gov/pubmed/28721067
http://dx.doi.org/10.2147/OTT.S128547

Ejemplares similares